NYSE:JOBY
NYSE:JOBYAirlines

Joby Aviation (JOBY) Explores New Defense Aircraft Class with L3Harris Technologies Partnership

Joby Aviation (JOBY) and L3Harris Technologies announced a collaboration to develop gas turbine hybrid VTOL aircraft for defense, planned to begin testing in 2025. Over the last quarter, Joby's stock rose 156%, standing out against a market backdrop marked by a 2.7% decline spurred by weak job reports and tariff concerns. The strategic alliance and the planned start of commercial air taxi flights in Dubai, alongside a significant site expansion in Marina, California, highlight Joby's growth...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter

CRISPR Therapeutics (CRSP) recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile...
NasdaqGS:RXRX
NasdaqGS:RXRXBiotechs

Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month

Recursion Pharmaceuticals (RXRX) experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company’s stock movement appeared isolated from these wider trends, which implies internal factors or...
NasdaqGS:RIVN
NasdaqGS:RIVNAuto

Rivian Automotive (RIVN) Expands With New East Coast HQ in Atlanta

Rivian Automotive (RIVN) has been actively expanding its operations, with recent developments including the establishment of a new East Coast headquarters in Atlanta and a new service center in Quebec. These efforts reflect the company's focus on enhancing its presence and infrastructure. However, RIVN's stock price saw a 3.8% decline over the past month. This decline aligns with broader market trends, as stocks experienced downturns due to weak job reports and heightened tariff concerns,...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing (QUBT) Seals First U.S. Commercial Sale With Top 5 Bank

Quantum Computing (QUBT) recently secured its first U.S. commercial sale for quantum cybersecurity solutions with a Top 5 U.S. Bank, a major milestone that highlights its advancements in the quantum communications market. This event coincided with a significant 84% price increase in the last quarter, potentially bolstered by strong Q1 earnings showing a net income turnaround and key executive appointments. While broader markets have faced declines due to economic uncertainties, Quantum...
NasdaqGS:ODFL
NasdaqGS:ODFLTransportation

Old Dominion Freight Line (ODFL) Sees 10% Stock Drop Over Last Quarter

Old Dominion Freight Line (ODFL) reported disappointing second-quarter earnings, with sales and net income both declining compared to the previous year. Despite affirmative news about a 7.7% dividend increase and share repurchase activity, ODFL saw its stock fall by 10.23% over the past quarter. This decline mirrored broader market concerns, as stocks generally fell due to weak job reports and renewed tariff worries. Old Dominion's on-market total return decline may have been amplified by...
NYSE:BRO
NYSE:BROInsurance

Brown & Brown (BRO) Reports Decline In Q2 2025 Net Income And Earnings Per Share

Brown & Brown (BRO) has reported mixed financial results for the second quarter of 2025, enjoying a revenue increase but experiencing a decline in net income and earnings per share. During the same week, the broader stock market faced a 3% drop, largely driven by investor reactions to weak employment data and new tariff policies. These market movements likely added weight to the company's stock price decline of nearly 11% over the past week. While the company's financials provided some...
NYSE:NEM
NYSE:NEMMetals and Mining

Newmont (NEM) Secures Akyem Lease Ratification With US$770 Million Divestiture Proceeds

Newmont (NEM) recently announced that the Ghanaian Parliament ratified the renewal of the Akyem East Mining Lease, with Zijin Mining Group paying $100 million as part of Newmont's divestiture program expected to generate $3.1 billion this year. This financial boost aligns with the company's capital priorities of debt reduction and shareholder returns. Over the last quarter, Newmont's share price experienced a 21% increase. Despite market volatility influenced by tariffs and weak jobs data,...
NYSE:CLF
NYSE:CLFMetals and Mining

Cleveland-Cliffs (CLF) Reports Q2 2025 Sales Decline to US$4934 Million

Cleveland-Cliffs (CLF) recently faced challenges as their second-quarter 2025 earnings revealed sales declined to USD 4,934 million, while registering a net loss of USD 483 million compared to a modest net income last year. Despite these disappointing financial results, Cleveland-Cliffs's share price rose by 15% over the past month. This performance unfolded against the backdrop of a broader market that saw similar gains in July, although markets experienced a downturn due to economic...
NasdaqGS:VRSN
NasdaqGS:VRSNIT

VeriSign (VRSN) Announced Increased Earnings

In July 2025, VeriSign (VRSN) expanded its buyback authorization and announced increased earnings, alongside a declared cash dividend. Despite these positive developments, the company's share price declined by 5.90% over the past month. This decline coincided with a broader market downturn, driven by global tariff uncertainties and disappointing job data. While VeriSign's solid financial results might have typically buoyed investor confidence, the market context placed downward pressure on...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Amgen (AMGN) Board Declares US$2.38 Dividend for Q3 2025

Amgen (AMGN) recently declared a $2.38 dividend per share, continuing its practice of rewarding shareholders, which aligns with a 5.6% price increase over the last quarter. During this period, Amgen announced successful Phase 3 clinical trial results, potentially boosting investor confidence. Additionally, amidst broader market volatility influenced by weak job reports and tariff concerns, Amgen's strong clinical outcomes and dividend declaration might have cushioned its stock against broader...